You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Pharmaceuticals Policy and Law - Volume 13, issue 3-4

Purchase individual online access for 1 year to this journal.

Price: EUR 100.00
The new international review, Pharmaceuticals Policy and Law, appears with the aim of studying and evaluating the legal status of medicinal products in the European Union, and its implications in other markets such as the USA and Japan, without neglecting the specific problems of developing countries.

Pharmaceuticals Policy and Law intends to participate in the process of world convergence of pharmaceutical legislation helped by a network of academic centers specializing in pharmaceutical law, without omitting a scientific, economic and social approach to medicinal products.

The specificity of medicinal products conditions their legal status. Legislation regulating other goods cannot be applied to them. To begin with, they are the result of scientific and technical innovation. Research policies determine their progress. The pharmaceutical industry is, by nature, multinational. But, next to these global trends, different traditions still remain at a national level. Within the EU, barriers to free trade in medicinal products still remain despite more than thirty years of harmonisation. The social dimension of medicinal products is complex and very significant in the preoccupations of our societies. Patenting is essential but not sufficient. The life-cycle of medicinal products is protected by professional responsibility, required in the general concept of health safety. It is important to remember their ethical dimension, including research and innovation in new fields such as genetic manipulation and biotechnology, which requires social consent to preserve human dignity and fundamental rights.
results per page

What is the evidence produced so far by the application of HTA to haemophilia care?

Authors: Berger, Karin | Schopohl, Dorothee | Schramm, Wolfgang

Article Type: Research Article

DOI: 10.3233/PPL-2011-0326

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 213-220, 2011

Price: EUR 27.50

Orphan drugs in oncology

Authors: Wild, Claudia | Hintringer, Katharina | Nachtnebel, Anna

Article Type: Research Article

DOI: 10.3233/PPL-2011-0327

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 223-232, 2011

Price: EUR 27.50

Health technology assessment – Plasma product industry view

Authors: Waller, Charles | Perry, Robert

Article Type: Research Article

DOI: 10.3233/PPL-2011-0328

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 235-241, 2011

Price: EUR 27.50

Patient involvement in HTA: What added value?

Authors: Facey, K.M.

Article Type: Research Article

Abstract: HTA is an interdisciplinary assessment of evidence and knowledge about the intended and unintended effects of using a health technology. Patients with rare diseases have valuable knowledge about the illness in the real-life setting, but too often their views are seen as anecdotal or biased. So, more needs to be done to elicit patients' perspectives to add value to HTA through effective participation of patients throughout the HTA process and collection of evidence about patients' perspectives … Show more

Keywords: Patient participation, technology assessment, qualitative research, rare diseases

DOI: 10.3233/PPL-2011-0329

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 245-251, 2011

Price: EUR 27.50

HTAi consumer and patient glossary

Article Type: Review Article

DOI: 10.3233/PPL-2011-0330

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 255-287, 2011

Price: EUR 27.50

Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national…

Article Type: Review Article

DOI: 10.3233/PPL-2011-0331

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 291-298, 2011

Price: EUR 27.50

Public Health. Title XIV. Article 168. (ex Article 152 TEC). Treaty on the Functioning of the European Union

Article Type: Review Article

DOI: 10.3233/PPL-2011-0334

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 299-300, 2011

Price: EUR 27.50

Council Directive 2000/43/EC of 29 June 2000 implementing the principle of equal treatment between persons irrespective of racial or ethnic origin

Article Type: Review Article

DOI: 10.3233/PPL-2011-0332

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 301-310, 2011

Price: EUR 27.50

Article 15, Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients' rights in cross-border healthcare

Article Type: Review Article

DOI: 10.3233/PPL-2011-0333

Citation: Pharmaceuticals, Policy and Law, vol. 13, no. 3-4, pp. 311-312, 2011

Price: EUR 27.50
Show more